Twist Bioscience(US:TWST)2022-11-18 13:51Financial Performance - Twist Bioscience reported record revenue of $2036 million for fiscal year 2022, a 54% increase year-over-year (YoY)[5] - Orders for fiscal year 2022 reached $226 million, a 42% increase YoY[5] - Q4 2022 revenue was $573 million and orders were $621 million[5] - Gross margin for fiscal year 2022 was 41%, and 449% for Q4 2022[35] - Net loss for fiscal year 2022 was $2348 million[35] Business Segments - Synthetic Biology revenue for fiscal year 2022 was $800 million with $907 million in orders[12] - NGS revenue for fiscal year 2022 was $993 million with $1041 million in orders[14] - Biopharma revenue for fiscal year 2022 was $242 million with $316 million in orders[19] - In fiscal year 2022, Twist Bioscience shipped 558000 genes[12] Customer Growth and Partnerships - Customer count increased from approximately 1700 in FY21 to approximately 2100 in Q4 FY22 and approximately 2900 in FY21 to approximately 3300 in FY22[9] - Twist Biopharma has 59 partners, 50 active programs, and 83 completed programs[17] - Twist Biopharma entered into 6 new partnerships in Q4 2022[19] Future Outlook - Expected revenue for fiscal year 2023 is projected to be between $261 million and $269 million[48] - Expected revenue for fiscal year 2024 is projected to be $350 million[48] - The company anticipates an early access launch of its first DNA data storage solution in late calendar 2023[23]